Short Interest in Avalon GloboCare Corp. (NASDAQ:ALBT) Drops By 46.4%

Avalon GloboCare Corp. (NASDAQ:ALBT) was the recipient of a large drop in short interest in the month of June. As of June 30th, there was short interest totaling 120,361 shares, a drop of 46.4% from the June 15th total of 224,716 shares. Currently, 1.3% of the shares of the company are short sold. Based on an average daily trading volume, of 1,909,636 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Avalon GloboCare from a “sell (e+)” rating to a “sell (e)” rating in a research note on Monday, June 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Avalon GloboCare has a consensus rating of “Sell”.

Avalon GloboCare Price Performance

Avalon GloboCare stock opened at $0.26 on Wednesday. The firm has a market cap of $3.09 million, a PE ratio of -0.07 and a beta of -0.03. The stock’s fifty day moving average price is $0.33 and its two-hundred day moving average price is $0.62. Avalon GloboCare has a one year low of $0.21 and a one year high of $4.74.

About Avalon GloboCare

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.